COMMENT | There are many key take away messages from the excellent management and governance of the US-CDC in relation to the Thrombosis Thrombocytopenia Syndrome (TTS) aka blood clots, associated with the viral vector-based Covid-19 vaccine from Johnson and Johnson (J&J).

1. The proactive action of the CDC and FDA to pause the use of the J&J vaccine, following reports of six cases (one fatal) of cerebral venous sinus thrombosis (CVST) with thrombocytopenia on April 13 and promptly issued a health alert.

2. The Advisory Committee on Immunisation Practices (ACIP) meeting the following day, again illustrates a sense of urgency to investigate this association of the J&J vaccine with the TTS.

3. Ten days later, the ACIP recommended to the CDC to lift the pause on the J&J vaccine for use in adults. The reason for the 10 days delay was to allow the ACIP to collect more information on the cases and to investigate other plausible mechanisms for this association...